hematinics

Summary

Summary: Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.

Top Publications

  1. ncbi Iron supplementation in pregnancy--does the preparation matter?
    Nir Melamed
    Department of Obstetrics and Gynecology, Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tiqwa, 49100, Israel
    Arch Gynecol Obstet 276:601-4. 2007
  2. ncbi A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    Marc A Pfeffer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2019-32. 2009
  3. ncbi Correction of anemia with epoetin alfa in chronic kidney disease
    Ajay K Singh
    Renal Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 355:2085-98. 2006
  4. ncbi Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Tilman B Drueke
    Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
    N Engl J Med 355:2071-84. 2006
  5. ncbi Ferric carboxymaltose in patients with heart failure and iron deficiency
    Stefan D Anker
    Department of Cardiology, Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin
    N Engl J Med 361:2436-48. 2009
  6. pmc Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
    J Glaspy
    Department of Medicine Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6996 USA
    Br J Cancer 102:301-15. 2010
  7. ncbi Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms
    Brandon K Hadland
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Clin Oncol 27:4217-26. 2009
  8. ncbi Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients
    Angus M Sinclair
    Amgen Inc, Thousand Oaks, California, USA
    Cancer 110:477-88. 2007
  9. ncbi Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial
    David B Van Wyck
    Arizona Health Sciences Center, University of Arizona College of Medicine, 1821 East Elm Street, Tucson, AZ 85719, USA
    Obstet Gynecol 110:267-78. 2007
  10. ncbi Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease
    Patrick S Parfrey
    Division of Nephrology, Health Sciences Center, Memorial University of Newfoundland, Prince Philip Drive, St John s, Newfoundland A1B 3V6, Canada
    J Am Soc Nephrol 16:2180-9. 2005

Research Grants

  1. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 2001
  2. Response to Iron Treatment for Restless Leg Syndrome
    Christopher Earley; Fiscal Year: 2004
  3. Nutritional/Inflammatory Evaluation of Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2005
  4. Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2008
  5. Epoetin Therapy and Survival of Hemodialysis Patients
    Dennis Cotter; Fiscal Year: 2006
  6. ITEM BANKING AND CAT FOR QUALITY OF LIFE OUTCOMES
    David Cella; Fiscal Year: 2008
  7. STRATEGIC CURRICULUM FOR CLINICAL RESEARCH
    Janice Gabrilove; Fiscal Year: 2004
  8. BP1 and Nuclear Hormone Signaling in Breast Cancer
    Janice Gabrilove; Fiscal Year: 2007
  9. Effects of N-acetylcystein on Muscle Fatigue in ESRD
    KIRSTEN JOHANSEN; Fiscal Year: 2007
  10. NCI TRANSITION CAREER DEVELOPMENT AWARD
    Theresa Gillespie; Fiscal Year: 2003

Detail Information

Publications282 found, 100 shown here

  1. ncbi Iron supplementation in pregnancy--does the preparation matter?
    Nir Melamed
    Department of Obstetrics and Gynecology, Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tiqwa, 49100, Israel
    Arch Gynecol Obstet 276:601-4. 2007
    ..To assess the use, side effects and discontinuation rates of iron preparations during pregnancy...
  2. ncbi A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    Marc A Pfeffer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2019-32. 2009
    ..Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested...
  3. ncbi Correction of anemia with epoetin alfa in chronic kidney disease
    Ajay K Singh
    Renal Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 355:2085-98. 2006
    ..Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined...
  4. ncbi Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Tilman B Drueke
    Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
    N Engl J Med 355:2071-84. 2006
    ..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established...
  5. ncbi Ferric carboxymaltose in patients with heart failure and iron deficiency
    Stefan D Anker
    Department of Cardiology, Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin
    N Engl J Med 361:2436-48. 2009
    ....
  6. pmc Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
    J Glaspy
    Department of Medicine Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6996 USA
    Br J Cancer 102:301-15. 2010
    ..To evaluate recent safety concerns regarding ESAs, we carried out a meta-analysis of controlled ESA oncology trials to examine whether ESA use affects survival, disease progression and risk of venous-thromboembolic events...
  7. ncbi Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms
    Brandon K Hadland
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Clin Oncol 27:4217-26. 2009
    ....
  8. ncbi Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients
    Angus M Sinclair
    Amgen Inc, Thousand Oaks, California, USA
    Cancer 110:477-88. 2007
    ..For this report, the authors reviewed the biology of EpoR in erythropoiesis and compared and contrasted the reported findings on the role of ESAs and EpoR in tumors...
  9. ncbi Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial
    David B Van Wyck
    Arizona Health Sciences Center, University of Arizona College of Medicine, 1821 East Elm Street, Tucson, AZ 85719, USA
    Obstet Gynecol 110:267-78. 2007
    ..To estimate efficacy of rapid, large-dose intravenous (IV) administration of ferric carboxymaltose compared with oral iron therapy in anemic postpartum women...
  10. ncbi Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease
    Patrick S Parfrey
    Division of Nephrology, Health Sciences Center, Memorial University of Newfoundland, Prince Philip Drive, St John s, Newfoundland A1B 3V6, Canada
    J Am Soc Nephrol 16:2180-9. 2005
    ..Normalization of hemoglobin in incident hemodialysis patients does not have a beneficial effect on cardiac structure, compared with partial correction...
  11. ncbi Erythropoietin treatment in patients with chronic heart failure: a meta-analysis
    P van der Meer
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    Heart 95:1309-14. 2009
    ..However, recent studies in patients with malignancies and renal failure have raised concerns about the safety of these agents...
  12. ncbi Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency
    Jorge Eduardo Toblli
    Hospital Aleman, Buenos Aires, Argentina
    J Am Coll Cardiol 50:1657-65. 2007
    ....
  13. ncbi Treatment of anemia with darbepoetin alfa in systolic heart failure
    Karl Swedberg
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    N Engl J Med 368:1210-9. 2013
    ..We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia...
  14. ncbi Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease
    Darren W Grabe
    Albany Nephrology Pharmacy Group, Albany College of Pharmacy, Albany, NY 12208, USA
    Am J Health Syst Pharm 64:S8-14; quiz S23-5. 2007
    ....
  15. ncbi Hemoglobin variability in patients with chronic kidney disease in the Netherlands
    Karien van der Putten
    Department of Internal Medicine, Meander Medical Center, Amersfoort the Netherlands
    Int J Artif Organs 32:787-93. 2009
    ..Information on hemoglobin cycling in Europe is limited. We investigated hemoglobin variability in the Netherlands. Hemodialysis and peritoneal dialysis patients were studied and pre-dialysis patients were enrolled...
  16. ncbi Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan
    Shingo Fukuma
    Department of Epidemiology and Healthcare Research, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Am J Kidney Dis 59:108-16. 2012
    ..We defined categories of ESA responsiveness and attempted to clarify their association with mortality...
  17. ncbi Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches
    Dirk J van Veldhuisen
    Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30 001, 9700RB Groningen, The Netherlands
    Nat Rev Cardiol 8:485-93. 2011
    ..Therefore, this treatment approach is likely to become an attractive option for patients with HF and iron deficiency, both with and without anemia...
  18. ncbi Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents
    Kirsten L Johansen
    University of California, San Francisco, CA, USA
    Am J Kidney Dis 55:535-48. 2010
    ..This potential increased risk needs to be weighed against the potential benefit of ESAs in improving various aspects of health-related quality of life, in particular, exercise tolerance and physical functioning...
  19. ncbi Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study
    Vincenzo Panichi
    Nephrology and Dialysis Versilia Hospital, Versilia, Italy
    Nephrol Dial Transplant 26:2641-8. 2011
    ..Here, we investigated how anaemia, ESA resistance and the plasma levels of biological markers of inflammation could influence all-cause and cardiovascular disease morbidity and mortality...
  20. ncbi Erythropoiesis-stimulating agent hyporesponsiveness
    David W Johnson
    Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Nephrology (Carlton) 12:321-30. 2007
    ..A practical algorithm for approaching the investigation and management of patients with ESA hyporesponsiveness is also provided...
  21. ncbi Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
    Julia Bohlius
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    Lancet 373:1532-42. 2009
    ..We therefore did a meta-analysis of randomised controlled trials in which these drugs plus red blood cell transfusions were compared with transfusion alone for prophylaxis or treatment of anaemia in patients with cancer...
  22. ncbi Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres
    Alison Roche
    King s College Hospital, London, UK
    Curr Med Res Opin 25:2971-6. 2009
    ..Monthly Hb values were obtained over a 12-month period. The frequency, duration, amplitude and direction of Hb fluctuations (Hb outside the range 11-12 g/dl in the Australian data-set and 11-12.5 g/dl in the UK data-set) were evaluated...
  23. pmc Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency
    Helen Finnamore
    National Heart and Lung Institute, Cardiovascular Sciences, Imperial College London, London, United Kingdom Diabetes and Nutritional Sciences Division, King s College London, School of Medicine, London, United Kingdom University of Liverpool Medical School, Liverpool, United Kingdom
    PLoS ONE 8:e76516. 2013
    ..The secondary objective was to examine whether iron deficiency can be attributed to under-replacement of epistaxis (nosebleed) hemorrhagic iron losses in hereditary hemorrhagic telangiectasia (HHT)...
  24. ncbi Erythropoietin: the swinging pendulum
    Howard S Oster
    The Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Leuk Res 36:939-44. 2012
    ..This review also provides tools to decide how and when to use ESAs safely, according to accepted guidelines...
  25. ncbi Hepcidin: clinical utility as a diagnostic tool and therapeutic target
    Daniel W Coyne
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Kidney Int 80:240-4. 2011
    ..We review the regulation of hepcidin, its role in CKD-related anemia, and discuss the potential for hepcidin as a clinical marker, and several investigational methods to lower hepcidin for treatment of anemia in CKD...
  26. ncbi American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 116:4045-59. 2010
    ..To update American Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer...
  27. ncbi Use of parenteral iron products and serious anaphylactic-type reactions
    Diane K Wysowski
    Office of Surveillance and Epidemiology, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Am J Hematol 85:650-4. 2010
    ..To help differentiate risk among the parenteral iron products, the brand name of the product always should be provided on medical records, death certificates, and adverse drug reaction reports...
  28. ncbi Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial
    David B Van Wyck
    DaVita, Inc, Tucson, Arizona, USA
    Transfusion 49:2719-28. 2009
    ..The objective was to evaluate efficacy and safety of rapid, large-dose intravenous (IV) administration of ferric carboxymaltose compared to oral iron in correcting iron deficiency anemia due to heavy uterine bleeding...
  29. ncbi Ferric carboxymaltose: a review of its use in iron-deficiency anaemia
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Drugs 69:739-56. 2009
    ..In patients with chronic kidney disease undergoing haemodialysis, a lower proportion of ferric carboxymaltose than iron sucrose recipients experienced at least one drug-related adverse event...
  30. ncbi Erythropoietic response and outcomes in kidney disease and type 2 diabetes
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 363:1146-55. 2010
    ..However, target-based strategies are confounded by each patient's individual hematopoietic response...
  31. ncbi What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
    Ajay K Singh
    Renal Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Nephrol Hypertens 19:420-4. 2010
    ..This article examines the potential mechanisms underlying adverse risk observed in four randomized controlled trials of anemia correction in chronic kidney disease (CKD) patients...
  32. pmc Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
    Fernando Carrera
    Eurodial, Dialysis Unit, Leiria, Portugal
    Nephrol Dial Transplant 25:4009-17. 2010
    ..We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epoetin beta and darbepoetin alfa administered once monthly...
  33. ncbi Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly
    Wladyslaw Sulowicz
    Clinic of Nephrology Collegium Medicum, Jagiellonian University, Cracow, Poland
    Clin J Am Soc Nephrol 2:637-46. 2007
    ..This study examined its efficacy and safety when administered up to once monthly in patients who have CKD and are on dialysis and randomly convert directly from epoetin alpha or beta one to three times weekly...
  34. pmc Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients
    Alexander Kainz
    Department of Nephrology, KH Elisabethinen, Linz, Austria
    Nephrol Dial Transplant 25:3701-6. 2010
    ..Therefore, we conducted a retrospective cohort study to evaluate ESA responsiveness and haemoglobin variability in association with mortality...
  35. ncbi Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 West Washington Square, Philadelphia, PA 19106, USA
    Oncologist 12:231-42. 2007
    ..To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa...
  36. pmc C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, Bessemer Road, London, SE5 9RS, UK
    Clin J Am Soc Nephrol 3:337-47. 2008
    ..This study examined the efficacy of C.E.R.A., a continuous erythropoietin receptor activator, for correcting anemia in patients who had chronic kidney disease (CKD) and were not on dialysis...
  37. pmc CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools
    Pradeep Sathyanarayana
    Maine Medical Center Research Institute, Scarborough, ME 04074, USA
    Blood 113:4955-62. 2009
    ..Based on these distinct erythropoietic and EPOR signaling properties, CNTO 530 holds excellent promise as a new EPO mimetic...
  38. pmc Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents
    Charles L Bennett
    The South Carolina College of Pharmacy, South Carolina Center of Economic Excellence for Medication Safety and Efficacy, and Southern Network on Adverse Reactions, Columbia, USA
    Arch Intern Med 170:1490-8. 2010
    ..We evaluated associations between pharmaceutical industry support and reported findings evaluating ESA effects on cancer cells...
  39. ncbi What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202 2699, USA
    Adv Chronic Kidney Dis 16:131-42. 2009
    ..For the individual patient, the therapeutic decision should center on what Hb is most appropriate at a "safe" ESA dose. Consequently, an Hb of 12 to 13 g/dL may be totally appropriate in some patient populations...
  40. ncbi Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    JAMA 297:1667-74. 2007
    ..The type of facility (profit, chain, and affiliation status) at which a patient receives dialysis might affect epoetin dosing patterns and has implications for future epoetin policies...
  41. ncbi Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients
    Csaba P Kovesdy
    Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, VA 24153, USA
    Adv Chronic Kidney Dis 16:109-16. 2009
    ..Particular attention is devoted to patients with non-dialysis-dependent CKD because the management of iron homeostasis in this group of patients poses additional intriguing questions...
  42. ncbi Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007
    Ying Wu
    Johnson and Johnson Pharmaceutical Services LLC, Malvern, Pennsylvania, USA
    Clin Ther 31:2416-32. 2009
    ..This study was conducted to evaluate data on chemotherapy-associated anemia and thrombocytopenia, and cycle delays in patients with cancer in a community oncology practice...
  43. ncbi Absence of functional EpoR expression in human tumor cell lines
    Susan Swift
    Department of Hematology, Medical Sciences, Amgen Inc, Thousand Oaks, CA 91320, USA
    Blood 115:4254-63. 2010
    ..These results conflict with the hypothesis that EpoR is functionally expressed in tumors...
  44. ncbi Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial
    Piotr Ponikowski
    Cardiac Department, Military Hospital, Wroclaw, Poland
    J Am Coll Cardiol 49:753-62. 2007
    ..This study sought to investigate whether darbepoetin alfa, an erythropoiesis-stimulating protein (ESP), improves exercise capacity in patients with symptomatic chronic heart failure (CHF) and anemia...
  45. ncbi Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial
    Melvin H Seid
    Lyndhurst Gynecologic Associates, Winston Salem, NC 27103, USA
    Am J Obstet Gynecol 199:435.e1-7. 2008
    ..The objective of the study was to evaluate the efficacy, safety, and tolerability of intravenous ferric carboxymaltose, compared with oral ferrous sulfate in women with postpartum anemia...
  46. ncbi The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome
    Donald S Silverberg
    Department of Nephrology, Tel Aviv Medical Center, Tel Aviv, Israel
    Heart Fail Rev 16:609-14. 2011
    ..However, adequately powered long-term placebo-controlled studies of ESA and of IV iron in CHF are still needed and are currently being carried out...
  47. ncbi Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial)
    Zoltan H Endre
    Christchurch Kidney Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand
    Kidney Int 77:1020-30. 2010
    ..Further, our study showed that a composite of these two biomarkers was insufficient for risk stratification in a patient population with a heterogeneous onset of injury...
  48. pmc Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
    Marcello Tonelli
    Department of Medicine, University of Alberta, Edmonton
    CMAJ 180:E62-71. 2009
    ..However, their safety and effectiveness is controversial. We did a systematic review of the clinical efficacy and harms of these agents in adults with anemia related to cancer or chemotherapy...
  49. ncbi Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Lung Cancer 76:478-85. 2012
    ..4%, placebo 1.0%) and pulmonary embolism (DA 1.8%, placebo 0.6%). These meta-analyses suggest that ESAs reduce transfusions without increasing mortality or disease progression in lung cancer patients undergoing chemotherapy...
  50. ncbi Anemia in chronic heart failure: can we treat? What to treat?
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, 13353 Berlin, Germany
    Heart Fail Rev 17:203-10. 2012
    ..The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure...
  51. pmc Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
    T Steinmetz
    Outpatient Clinic for Oncology and Haematology, Cologne German
    Ann Oncol 24:475-82. 2013
    ..This study evaluated effectiveness and tolerability of ferric carboxymaltose (FCM) in routine treatment of anaemic cancer patients...
  52. ncbi Peginesatide in patients with anemia undergoing hemodialysis
    Steven Fishbane
    Hofstra North Shore LIJ School of Medicine, Great Neck, NY 11021, USA
    N Engl J Med 368:307-19. 2013
    ..Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential therapy for anemia in patients with advanced chronic kidney disease...
  53. ncbi Anemia of hematologic malignancies: what are the treatment options?
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelmin Hospital, University of Vienna, Austria
    Semin Oncol 29:45-54. 2002
    ..Representative studies on the efficacy of epoetin alfa in anemic patients with hematologic malignancies as well as models to predict response to epoetin alfa treatment are summarized...
  54. ncbi Ferumoxytol for the treatment of iron deficiency
    Mitchell H Rosner
    Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA
    Expert Rev Hematol 4:399-406. 2011
    ..This article examines existing clinical data and posits reasons for the labeling change. Potential future use of this formulation is opined...
  55. ncbi Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis
    Iain C Macdougall
    Renal Unit, King s College Hospital, London, United Kingdom
    N Engl J Med 368:320-32. 2013
    ..We evaluated the safety and efficacy of peginesatide, as compared with another ESA, darbepoetin, in 983 such patients who were not undergoing dialysis...
  56. ncbi Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients
    Eric D Weinhandl
    Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Minneapolis, MN 55404, USA
    Am J Nephrol 34:298-308. 2011
    ..Appropriately designed observational studies are needed to clarify the association of ESA dosing with mortality risk...
  57. ncbi Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
    Takeshi Hasegawa
    Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
    Kidney Int 79:340-6. 2011
    ..Thus, this bundling policy was associated with reduced rHuEPO doses, increased intravenous iron use, and stable hemoglobin levels in Japanese patients receiving hemodialysis...
  58. ncbi A new concept for the differential diagnosis and therapy of anaemia in cancer patients
    H Tilman Steinmetz
    Oncology Outpatient Clinic in Cologne, Cologne, Germany
    Support Care Cancer 19:261-9. 2010
    ....
  59. ncbi Oral versus high dose parenteral iron supplementation in pregnancy
    A Kumar
    Department of Obstetrics and Gynecology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi 110002, India
    Int J Gynaecol Obstet 89:7-13. 2005
    ..To compare the effect of daily oral iron supplementation with two injections of high dose parenteral iron...
  60. ncbi Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer
    Peter J Hoskin
    Marie Curie Research Wing for Oncology, Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK
    J Clin Oncol 27:5751-6. 2009
    ..To evaluate the effect of epoetin alfa on local disease-free survival (DFS), overall survival (OS), and cancer treatment-related anemia and fatigue in patients with head and neck cancer receiving radical radiotherapy with curative intent...
  61. ncbi Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment
    Louis B Harrison
    Department of Radiation Oncology, Beth Israel Medical Center St Luke s Roosevelt Hospital Center, New York, N Y 10003, USA
    Oncology 63:11-8. 2002
    ..Radiation oncologists need to be aware of the possibility of anemia in cancer patients undergoing radiotherapy so that timely intervention can be instituted whenever anemia is diagnosed...
  62. ncbi Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma
    Eirini Katodritou
    Department of Hematology, Theagenion Cancer Center, Thessaloniki, Greece
    Am J Hematol 83:697-701. 2008
    ..001). These results indicate that ESA may have a detrimental impact on MM patients' outcomes and, thus, in this context, they should be used with rigorous criteria...
  63. ncbi Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    J Natl Cancer Inst 97:489-98. 2005
    ..Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant diseases...
  64. ncbi Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly
    Anil K Agarwal
    The Ohio State University, Internal Medicine, Division of Nephrology, Columbus, OH 43210, USA
    J Am Med Dir Assoc 7:S7-S12; quiz S17-21. 2006
    ..Poor response to treatment with ESP can be due to many factors, including presence of iron deficiency, inflammation, continued blood loss, and hemoglobinopathy...
  65. ncbi Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study
    Francesco Locatelli
    Department of Nephrology, Dialysis and Renal Transplant, Alessandro Manzoni Hospital, Lecco, Italy
    Nephrol Dial Transplant 25:2846-50. 2010
    ..These recommendations are not intended to represent a new guideline as they are not the result of a systematic review of the evidence...
  66. ncbi A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry
    T Steinmetz
    Outpatient Clinic, Sachsenring, Cologne, Germany
    Eur J Cancer Care (Engl) 20:493-502. 2011
    ..Prospective clinical trials using QOL as end point and evaluating diagnostics in cancer-associated anaemia are warranted...
  67. ncbi Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation
    Shi Nae Kim
    Department of Hematology Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea
    J Clin Apher 24:173-9. 2009
    ..However, the CD8+ cell count was significantly lower in the triple regimen group. The role of a lower CD8+ cell count in the graft may need to be elucidated in the future...
  68. pmc Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer
    Dawn L Hershman
    Columbia University Medical Center, 161 Fort Washington Ave, 10 1068, New York, NY 10032, USA
    J Natl Cancer Inst 101:1633-41. 2009
    ..Erythropoiesis-stimulating agents (erythropoietin and darbepoietin) have been approved to reduce the number of blood transfusions required during chemotherapy; however, concerns about the risks of venous thromboembolism and mortality exist...
  69. ncbi Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009
    Deborah Regidor
    Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Nephrol Dial Transplant 26:1583-91. 2011
    ..The extent to which these events influenced ESA dosing and Hb levels in patients with chronic kidney disease not on dialysis (CKD-NOD) is not known...
  70. ncbi Developments in the therapeutic use of erythropoiesis stimulating agents
    Wolfgang Jelkmann
    Institute of Physiology, University of Luebeck, Luebeck, Germany
    Br J Haematol 141:287-97. 2008
    ..Finally, potential novel indications are considered for the use of rHuEPO and its analogues as pleiotropic cytoprotectant agents for cardio-, nephro-, hepato- and neuroprotection...
  71. ncbi Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss
    Alejandro C Arroliga
    Cleveland Clinic, Cleveland, OH, USA
    Crit Care Med 37:1299-307. 2009
    ....
  72. pmc Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients
    Iain C Macdougall
    Renal Unit, King s College Hospital, London, United Kingdom
    Clin J Am Soc Nephrol 6:2579-86. 2011
    ..We report the first assessment of its efficacy and safety in correcting renal anemia in a population of 139 nondialysis chronic kidney disease patients...
  73. ncbi Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial
    Andreas Engert
    University Hospital of Cologne, Department of Internal Medicine, Kerpener Str 62, Cologne, Germany 50924
    J Clin Oncol 28:2239-45. 2010
    ....
  74. ncbi RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy
    W Eisterer
    Medical University Innsbruck, Dept Internal Medicine, Austria
    Curr Med Res Opin 27:355-63. 2011
    ..Darbepoetin alfa (DA) 500 µg administered once every 3 weeks (Q3W) has been shown to be effective in patients with chemotherapy-induced anaemia...
  75. pmc Transfusion burden among patients with chronic kidney disease and anemia
    Elizabeth V Lawler
    Veterans Administration Boston Healthcare System, 150 S Huntington Avenue 151MAV, Boston, MA 02130
    Clin J Am Soc Nephrol 5:667-72. 2010
    ..Although well-described for patients who require dialysis, information on transfusion burden related to anemia in the nondialysis patient population with chronic kidney disease (CKD) is lacking...
  76. ncbi Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells
    Angus M Sinclair
    Department of Hematology, Amgen Inc, Thousand Oaks, CA, USA
    Blood 115:4264-72. 2010
    ..Taken together, our data challenge the notion of presence or function of EpoR on nonhematopoietic cells, and call into question the preclinical basis for clinical studies exploring direct, "pleiotropic" actions of ESAs...
  77. ncbi The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials
    D Cella
    Northwestern University and Evanston Northwestern Healthcare, Evanston, IL 60201, USA
    Ann Oncol 15:979-86. 2004
    ..Anemia is common in cancer and has been associated with fatigue and reduced health-related quality of life (HRQOL). We report the association between hemoglobin and fatigue and the impact of reducing fatigue on several domains of HRQOL...
  78. ncbi Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa
    D L Patrick
    University of Washington, Box 357660, Seattle, WA 98195 7660, USA
    Eur J Cancer 39:335-45. 2003
    ..These methods provide one means for interpreting the clinical relevance of changes in HrQOL evaluated in clinical trials...
  79. pmc Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study
    Bernard Canaud
    Hopital Lapeyronie, Service de Nephrologie, Montpellier, France
    Nephrol Dial Transplant 23:3654-61. 2008
    ..Phase III results have demonstrated that C.E.R.A. administered once every 4 weeks effectively maintains stable Hb levels in patients with CKD on dialysis...
  80. pmc Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
    ..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
  81. ncbi Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 20162, Milano, Italy
    J Clin Oncol 26:1619-25. 2008
    ..We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin...
  82. ncbi Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
    Charles L Bennett
    VA Chicago Healthcare System, Department of Medicine, Northwestern University Feinberg School of Medicine, and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    JAMA 299:914-24. 2008
    ..Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs...
  83. ncbi A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy
    A Khalafallah
    Launceston General Hospital LGH, University of Tasmania, Tasmania, Australia
    J Intern Med 268:286-95. 2010
    ..Iron deficiency anaemia is the most common deficiency disorder in the world, affecting more than one billion people, with pregnant women at particular risk...
  84. ncbi Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
    Laurent Bastit
    Centre Frédéric Joliot, Rouen, France
    J Clin Oncol 26:1611-8. 2008
    ..This study was designed to evaluate the efficacy and safety of darbepoetin alpha given with IV iron versus with local standard practice (oral iron or no iron)...
  85. ncbi Anemia in renal disease: diagnosis and management
    Christina E Lankhorst
    Division of Nephrology, University Hospitals Case Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, USA
    Blood Rev 24:39-47. 2010
    ..Correction of iron deficiency can improve anemia and reduce ESA requirements. Partial, but not complete, correction of anemia is associated with improved outcomes in patients with CKD...
  86. doi The role of intravenous iron in anemia management and transfusion avoidance
    Michael Auerbach
    Private Practice, Baltimore, Maryland, USA
    Transfusion 48:988-1000. 2008
  87. ncbi Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia
    David E Leaf
    Department of Medicine, New York University School of Medicine, New York, New York, USA
    Kidney Int 75:15-24. 2009
    ..Beyond this range, additional normalization of hemoglobin (to 12-14 g/dl) results in continued (albeit blunted) improvements in HRQOL...
  88. ncbi Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
    John J V McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Eur J Heart Fail 11:795-801. 2009
    ..Whether correcting anaemia can improve outcomes is unknown...
  89. ncbi Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management
    Mehmet Kanbay
    Department of Medicine, Section of Nephrology, Fatih University School of Medicine, Ankara, Turkey
    Blood Purif 29:1-12. 2010
    ..The aim of the present review is to provide an update of the recent literature on causes and possible management of ESA-resistant anemia in CKD patients...
  90. ncbi Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
    Michael Hedenus
    Medical Department, Sundsvall Hospital, Sundsvall, Sweden
    Br J Haematol 119:79-86. 2002
    ..Confirmative studies at doses of 2.25 and/or 4.5 microg/kg/week in this population are warranted...
  91. pmc Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease
    Roberto Minutolo
    Nephrology Division, Second University of Naples Santa Maria del Popolo degli Incurabili Hospital Azienda SanitariaLocale, Solofra, Italy
    Clin J Am Soc Nephrol 4:552-9. 2009
    ..Intrapatient variability of hemoglobin (Hb) is a newly proposed determinant of adverse outcome in chronic kidney disease (CKD). We evaluated whether intensity of epoetin therapy affects Hb variability and renal survival in nondialysis CKD...
  92. pmc The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study
    Adrian Covic
    Dialysis and Transplantation Center, Parhon University Hospital, Lasi, Romania
    Nephrol Dial Transplant 25:2722-30. 2010
    ..This study primarily investigated the safety, and also the efficacy, of ferric carboxymaltose (FCM), a next-generation i.v. iron formulation, given as a bolus-push injection in patients with CKD undergoing maintenance haemodialysis (HD)...
  93. ncbi Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
    James R Wright
    Juravinski Cancer Center at Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Clin Oncol 25:1027-32. 2007
    ..We designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic patients with advanced non-small-cell carcinoma of the lung (NSCLC)...
  94. ncbi The therapeutic equivalence of complex drugs
    Huub Schellekens
    Department of Pharmaceutical Sciences, Utrecht University, P O Box 80 082, 3508 TB Utrecht, The Netherlands
    Regul Toxicol Pharmacol 59:176-83. 2011
    ....
  95. ncbi Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation
    A K Singh
    Renal Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Kidney Int 71:1163-71. 2007
    ..We conclude that none of the studied markers is a good predictor of response to anemia treatment in this patient sub-population...
  96. ncbi Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery
    Katia Boven
    Service d Hematologie Biologique, Hopital Hotel Dieu, 1 Place du Parvis Notre Dame, 75181 Paris cedex 4, France
    Nephrol Dial Transplant 20:iii33-40. 2005
    ..In conclusion, these data strongly suggest that leachates were the critical contributory factor in the increased incidence of antibody-mediated PRCA attributed to EPREX/ERYPO...
  97. ncbi Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide
    Sylke Nagel
    Hospital Martha Maria, Halle Doelau, Germany
    Clin Lung Cancer 12:62-9. 2011
    ..Addition of darbepoetin alfa to chemotherapy lowered the need for blood transfusions and did not affect measures of survival and objective response...
  98. ncbi The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure
    Marc Klapholz
    Department of Cardiology, New Jersey Medical School, Newark, NJ, USA
    Eur J Heart Fail 11:1071-7. 2009
    ..To assess the safety and tolerability of darbepoetin alfa (DA) in the treatment of anaemia in heart failure (HF)...
  99. ncbi Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent
    Abraham Jacob
    Department of Haematology and Renal Medicine, Royal Wolverhampton Hospitals, New Cross Hospital, Wolverhampton, West Midlands, WV10 0QP
    Nephrol Dial Transplant 21:2963-5. 2006
  100. pmc Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, California 41984, USA
    Clin J Am Soc Nephrol 4:630-7. 2009
    ....
  101. ncbi Erythropoietins: a common mechanism of action
    Steve Elliott
    Amgen Inc, Thousand Oaks, CA 91320 1799, USA
    Exp Hematol 36:1573-84. 2008
    ..PEGylation of EPO (addition of polyethylene glycol) has been used to further extend the terminal half-life. Also, new strategies are under investigation for stimulating erythropoiesis through activation of the EPO receptor...

Research Grants63

  1. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 2001
    ..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..
  2. Response to Iron Treatment for Restless Leg Syndrome
    Christopher Earley; Fiscal Year: 2004
    ..An expected finding that IV iron reduces the brain iron insufficiency and dramatically reduces the RLS symptoms strongly supports our model of RLS caused by brain iron insufficiency. ..
  3. Nutritional/Inflammatory Evaluation of Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2005
    ....
  4. Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  5. Epoetin Therapy and Survival of Hemodialysis Patients
    Dennis Cotter; Fiscal Year: 2006
    ..Our goal is to insure that treatment !patterns for this high-risk population are rationally based to provided the patients with the best possibilities for survival. ..
  6. ITEM BANKING AND CAT FOR QUALITY OF LIFE OUTCOMES
    David Cella; Fiscal Year: 2008
    ..We will also monitor treatment/management changes, and evaluate acceptability of computer assessments and the perceived benefits of the recommendations. ..
  7. STRATEGIC CURRICULUM FOR CLINICAL RESEARCH
    Janice Gabrilove; Fiscal Year: 2004
    ..abstract_text> ..
  8. BP1 and Nuclear Hormone Signaling in Breast Cancer
    Janice Gabrilove; Fiscal Year: 2007
    ..abstract_text> ..
  9. Effects of N-acetylcystein on Muscle Fatigue in ESRD
    KIRSTEN JOHANSEN; Fiscal Year: 2007
    ..To determine whether patients with ESRD generate excessive oxidative stress in response to exercise and whether muscle fatigue can be ameliorated by short-term treatment with N-acetylcysteine. [unreadable] [unreadable] [unreadable]..
  10. NCI TRANSITION CAREER DEVELOPMENT AWARD
    Theresa Gillespie; Fiscal Year: 2003
    ....
  11. ANABOLIC STEROIDS AND EXERCISE IN HEMODIALYSIS
    KIRSTEN JOHANSEN; Fiscal Year: 2002
    ..abstract_text> ..
  12. DOPAMINERGIC FUNCTION IN RESTLESS LEGS SYNDROME
    Christopher Earley; Fiscal Year: 2001
    ..The authors would also explore relationships between iron and CSF measures of dopaminergic activities, which could provide the basis for entirely new research and treatment approaches to RLS. ..
  13. Antiviral Therapy in African Americans with HCV
    Nezam Afdhal; Fiscal Year: 2005
    ..Specimens of liver tissue and serum will be collected for basic studies on viral resistance. These studies should help determine the best therapy for AA with HCV. ..
  14. Proteomics and Biomarkers for Hepatocellular Cancer
    Nezam Afdhal; Fiscal Year: 2004
    ..These studies may lead to identification of more specific and sensitive biomarkers for HCC in HCV which can then be validated further in prospective clinical trials. ..
  15. Dopamine and Iron in Restless Legs Syndrome
    Christopher Earley; Fiscal Year: 2006
    ..Using CSF and MRI measurements of iron will assess the CNS iron status. RLS severity will be based on subjective (rating scale and diary) and objective (PSG) measurements. ..
  16. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2002
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  17. DETERMINING THE GENETICS OF RESTLESS LEGS SYNDROME
    Christopher Earley; Fiscal Year: 2003
    ....
  18. Hospital and Community Acquired Acute Renal Failure
    Glenn Chertow; Fiscal Year: 2006
    ..This study will efficiently inform the Nephrology community by providing a foundation of fundamental information (ARF definitions, incidence, consequences and costs) upon which a clinical trials network can be built. ..
  19. Pathophysiology of Heart Failure with a Normal Ejection Fraction in the Elderly
    Mathew S Maurer; Fiscal Year: 2010
    ....
  20. BALTIMORE PEDIATRIC EYE SURVEY
    James Tielsch; Fiscal Year: 2007
    ..The analysis will focus on estimating the age and race-specific prevalence of ocular disorders in this group and on assessing the association of selected risk factors with the prevalence of these disorders. ..
  21. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007
    ..CME credit for attending physicians will be provided. ..
  22. Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors
    ELIZABETH ANN contact COLEMAN; Fiscal Year: 2010
    ..Thus, this study will accelerate nursing advancements to the "Science of Health". ..
  23. Physician Training Program in Neonatal Biology
    John Widness; Fiscal Year: 2007
    ..With NIH support beyond that which the investigators currently enjoy, the investigators will be able to significantly enhance the research training experiences they offer their postdoctoral physician trainees in neonatal medicine. ..
  24. The function of I(3)mbt in hematopoietic cancers
    Stephen Nimer; Fiscal Year: 2007
    ..The PcG family of proteins is being increasingly implicated in carcinogenesis, and these studies will provide insights into the role that l(3)mbt plays in hematologic malignancies. ..
  25. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007
    ..abstract_text> ..
  26. New Evidence on the Persistence of High Health Spending
    Richard Hirth; Fiscal Year: 2009
    ..We will provide an example of how such estimates can inform the evaluation of risk-adjustment and reinsurance as mechanisms to improve the functioning of small group health insurance markets. ..
  27. Treatment of Endometriosis with NA vs GnRH Agonist
    Ozgul Muneyyirci Delale; Fiscal Year: 2008
    ..The objectives will be compared between the group at 12, 24 and 52 weeks of treatment and at 6 month intervals during the follow-up period. ..
  28. Hearing Loss and Quality of Life of Children and Youth
    Donald Patrick; Fiscal Year: 2009
    ....
  29. The Coronary Screening for Kidney Transplantation (COST) Study
    Bertram Kasiske; Fiscal Year: 2008
    ..The money spent on these procedures might be better directed to health care measures of proven efficacy. [unreadable] [unreadable] [unreadable]..
  30. Pharmacokinetics & Genomics in Glomerular Diseases
    MELANIE JOY; Fiscal Year: 2008
    ..The selection of collaborators with expertise in the areas of this grant will enhance the career development of Dr. Joy. ..
  31. Zinc and Biobehavioral development in early childhood
    Laura Caulfield; Fiscal Year: 2008
    ..Strengths of the study include the experimental design, the innovative methods proposed to measure cognitive development, and the uniqueness of the study site. ..
  32. Quality of Life of Overweight Youth: Multicultural View
    Donald Patrick; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  33. Gene expression and anemia of chronic renal failure
    Saul Nurko; Fiscal Year: 2008
    ..abstract_text> ..
  34. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    Stephen Nimer; Fiscal Year: 2007
    ..abstract_text> ..
  35. Iron Therapy in Renal Disease: Potential Toxicities
    RICHARD ZAGER; Fiscal Year: 2008
    ..Potential reasons for these differences will be assessed, with the ultimate goal of defining the safest way of administering parenteral irons to renal disease patients. ..
  36. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  37. MECHANISM OF RETINAL ISCHEMIA
    DANIEL ROSENBAUM; Fiscal Year: 2005
    ..b) Multi-modal therapy employing caspase inhibitor(s) and anti-excitotoxic strategies work synergistically toreduce ischemic retinal damage. ..
  38. Cardiovascular Causes of Falls/Syncope in the Elderly
    Mathew Maurer; Fiscal Year: 2005
    ..abstract_text> ..
  39. Stigma & Quality of Life of Youth w/Facial Differences
    Donald Patrick; Fiscal Year: 2005
    ..Participants for this study will be recruited from sites in Seattle, Chicago, and Chapel Hill, NC. ..
  40. LONG-TERM OUTCOME OF BLOOD AND MARROW TRANSPLANTATION
    J Rizzo; Fiscal Year: 2003
    ..abstract_text> ..
  41. Newborn Antiseptic Washing and Neonatal Mortality-Nepal
    James Tielsch; Fiscal Year: 2005
    ..The umbilical cord infection trial will require only one year of recruitment to obtain adequate numbers to detect a 20% in infection rates in the treatment groups. ..
  42. Live Unrelated Kidney Donor & Sibling Follow-up Study
    Bertram Kasiske; Fiscal Year: 2005
    ..Altogether, this study will provide useful information that will improve the informed consent for living kidney donors and enhance our knowledge of the role of the kidney, if any, in CVD. ..
  43. Nutritional Influences on Aresenic Toxicity
    Mary Gamble; Fiscal Year: 2006
    ..abstract_text> ..
  44. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  45. CARDIAC VALVE CALCIFICATION
    Emile Mohler; Fiscal Year: 2003
    ..2. To investigate mechanisms of valve calcification using a cell culture model of calcification. 3. To examine therapeutic strategies to inhibit valve calcification with a bisphosphonate in cell culture. ..
  46. AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    Alexandra Levine; Fiscal Year: 2005
    ..The expertise of our labs and experience will be available to the AMC, which will be considered of the highest priority for our Group. ..
  47. Phase II Trial of Thalidomide in Primary Amyloidosis
    Angela Dispenzieri; Fiscal Year: 2002
    ..The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease. ..
  48. ACUTE RENAL FAILURE--IMPACT OF FLUORINATED ANESTHETICS
    RICHARD ZAGER; Fiscal Year: 2001
    ....
  49. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  50. Human Defensins in Phagocytes and Epithelia
    Tomas Ganz; Fiscal Year: 2004
    ..In the aggregate, these studies will expand our understanding of is ubiquitous and multifunctional family of human host defense peptides, this time also in their role as effectors of innate immunity in epithelia. ..
  51. THE ROLE OF INFLAMMATION IN ANEMIA OF THE ELDERLY
    Tomas Ganz; Fiscal Year: 2010
    ..This study is designed to find how inflammation causes anemia in the elderly and how the disease processes are changed by available treatments. ..
  52. Erythropoietin receptors in breast cancer
    MURAT ARCASOY; Fiscal Year: 2008
    ..abstract_text> ..
  53. Hypoxia VHL nad HIF in Renal Tumor Development
    Volker Haase; Fiscal Year: 2008
    ..Ultimately they have the potential to create a murine model of VHL associated renal tumors. ..
  54. The role of hemojuvelin in the regulation of iron metabolism
    Tomas Ganz; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  55. In vivo Substrate Utilization in the Newborn Rat Brain
    Raghavendra Rao; Fiscal Year: 2006
    ....
  56. Exercise to Relieve Cancer-Related Insomnia and Fatigue
    Elizabeth Coleman; Fiscal Year: 2007
    ..As their physical activity and functional status improve, patients can continue to manage their activities of daily living and may be more likely to continue cancer treatment, thus increasing their survival chances. ..
  57. Osteoporosis Prevention in Early Stage Breast Cancer
    Dawn Hershman; Fiscal Year: 2006
    ..abstract_text> ..
  58. INNATE HOST DEFENSE IN THE HUMAN VAGINA
    Tomas Ganz; Fiscal Year: 2004
    ..abstract_text> ..
  59. FTI Biology & Treatment of Myeloproliferative Disorders
    Jason Gotlib; Fiscal Year: 2005
    ..If clinically efficacious, further studies of R115777 in MPDs will be warranted...